Method Article
* Wspomniani autorzy wnieśli do projektu równy wkład.
This methodology aims to evaluate biomaterial cytotoxicity through the preparation of soluble extracts, using viability assays and phenotypic analysis, including flow cytometry, RT-PCR, immunocytochemistry, and other cellular and molecular biology techniques.
Biomaterials contact directly or indirectly with the human tissues, making it important to evaluate its cytotoxicity. This evaluation can be performed by several methods, but a high discrepancy exists between the approaches used, compromising the reproducibility and the comparison among the obtained results. In this paper, we propose a protocol to evaluate biomaterials cytotoxicity using soluble extracts, which we use for dental biomaterials. The extracts preparation is detailed, from pellets production to its extraction in a culture medium. The biomaterials cytotoxicity evaluation is based on metabolic activity using the MTT assay, cell viability using the Sulphorhodamine B (SBR) assay, cell death profile by flow cytometry, and cell morphology using May-Grünwald Giemsa. Additional to cytotoxicity evaluation, a protocol to evaluate cell function is described based on the expression of specific markers assessed by immunocytochemistry and PCR. This protocol provides a comprehensive guide for biomaterials cytotoxicity and cellular effects evaluation, using the extracts methodology, in a reproducible and robust manner.
Biocompatibility can be defined as the capacity of a material to integrate tissue and induce a favorable therapeutic response, free of local and systemic damages1,2,3. Biocompatibility evaluation is crucial for the development of any material intended for medical use. Therefore, this protocol provides a systematic and comprehensive approach for every researcher aiming to develop new biomaterials or studying new applications for existing biomaterials.
In vitro cytotoxicity tests are widely used as the first phase for biocompatibility evaluation, using primary cell cultures or cell lines. The results constitute a first indicator of potential clinical application. Besides being vital for the biomaterial development, this testing is mandatory to comply with current regulations for market introduction, from EUA and EU regulators (FDA and CE certification)4,5,6,7,8. Moreover, standardized testing in biomedical research provides a significant advantage in terms of reproducibility and comparison of results from different studies on similar biomaterials or devices9.
International Organization for Standardization (ISO) guidelines are widely used by multiple independent commercial, regulatory, and academic laboratories for testing materials in an accurate and reproducible manner. The ISO 10993-5 refers to the in vitro cytotoxicity assessment and the ISO 10993-12 reports to sampling preparation10,11. For biomaterial testing three categories are provided, to be selected according to the material type, contacting tissues, and the treatment goal: extracts, direct contact, and indirect contact8,11,12,13. Extracts are obtained by enriching a cell culture medium with the biomaterial. For the direct contact tests, the biomaterial is placed directly on the cell cultures, and, in indirect contact, incubation with the cells is performed separated by a barrier, such as an agarose gel11. Appropriate controls are mandatory, and a minimum of three independent experiments should be performed5,8,10,11,14.
It is critical to simulate or exaggerate clinical conditions to determine the cytotoxic potential. In the case of extracts testing, the material's surface area; the medium volume; the medium and the material pH; the material solubility, osmolarity and diffusion ratio; and the extraction conditions such as agitation, temperature, and time influence media enrichmen5.
The methodology allows the quantitative and qualitative evaluation of cytotoxicity of several pharmaceutical formulations, both solid and liquid. Several assays can be performed, such as neutral red uptake test, colony formation test, MTT assay, and XTT assay5,10,14.
Most cytotoxicity assessment studies published use simpler assays, namely MTT and XTT, which provide limited information. Evaluating biocompatibility should not only involve the assessment of cytotoxicity but also bioactivity of a given test material2, as this protocol endorses. Additional evaluation criteria should be used when justified and documented. Thus, this protocol aims to provide a comprehensive guide, detailing a set of methods for the biomaterial cytotoxicity evaluation. Besides, the evaluation of different cellular processes, namely the type of cell death, cell morphology, cell function in the synthesis of specific proteins, and specific tissue production, are described.
1. Pellets preparation
2. Obtaining the biomaterials' extracts
NOTE: All procedures should be performed under strict sterile conditions.
Figure 1: Scheme of the preparation and dilutions of soluble extracts. Please click here to view a larger version of this figure.
3. Cell incubation with the biomaterials’ extracts
4. Evaluation of the metabolic activity
5. Cell death evaluation
NOTE: To perform this evaluation a minimum of 106 cells per condition should be used.
6. Morphology evaluation
7. Cell function assessment through reverse transcription polymerase chain reaction (RT-PCR)
NOTE: To perform this evaluation a minimum of 2x106 cells per condition should be used. As an example, alkaline phosphatase is presented as a gene of interest for odontoblasts activity evaluation. Other genes of interest can be seen in Table 1.
8. Cell function assessment through protein identification
NOTE: According to the study goal, select the specific proteins to be evaluated. As an example, dentin sialoprotein (DSP) is presented as a protein of interest for odontoblasts activity evaluation. Other proteins of interest can be seen in Table 1.
9. Mineralization assessment through Alizarin Red S assay
The representative results here refer to the study of dental biomaterials. The extract methodology allows to obtain a cytotoxicity profile and cell function after exposition to the dental materials, regarding effects on metabolic activity (Figure 2), cell viability, cell death profile and cell morphology (Figure 3), and specific proteins expression (Figure 4).
The MTT assay is used to obtain a quick overview of the cytotoxicity of the materials in a straightforward way. A comparison between two or more materials can be made (Figure 2); a severe reduction of the metabolic activity, even when at low (6.25%) and medium concentrations (50%), indicates higher toxicity (Figure 2a). At the same time, less cytotoxic materials present only lighter or no reduction (Figure 2b). Comparisons between different time points allow determining more immediate cytotoxic effects or at later stages.
Effects on cell viability provide important information about viable cell reduction, which can compromise the tissues' capacity to recover after a damaging effect. The determination of the percentage of viable cells allows comparing material cytotoxicity; more cytotoxic materials induce higher cell death for the same concentration (Figure 3a and 3b). Reductions superior to 30% are critical and define materials at risk of low biocompatibility (Figure 3a). This information is completed with the cell death profile (Figure 3a and 3b). In the representative results, more cytotoxic materials are characterized by an accentuated decrease in cell viability and for a late apoptosis and necrosis cell death profile (Figure 3a), while less cytotoxic ones present less cell death and a more apoptotic and late apoptotic profile (Figure 3b).
The information obtained from the cellular morphology evaluation (Figure 3c) complements the cell viability evaluation. Changes from the cell´s typical morphology can indicate an apoptotic or necrotic profile16. Also, additional information can be obtained from this protocol, like the observation of material particles (red arrows, Figure 3C).
Specific markers, fundamental to cell function, affected by the extract exposure can be evaluated by several techniques, as immunohistochemistry, PCR, flow cytometry, blotting, or colorimetric assays (Table 1). Representative results of the DSP expression after exposure to extracts are shown in Figure 4a, and it can be seen that some materials (tricalcium silicates cements) stimulate the cells to increase protein expression. In contrast, others (calcium hydroxide cements) promote a significant decrease in protein expression, independently of viability loss. In both cases, the concentration of the extracts directly influences the protein expression.
In the MDPC-23 cell line of the odontoblast phenotype, the formation of mineralization deposits is characteristic. The protocol for the mineralized deposits identification and quantification allows evaluating the specific function of this type of specialized cells. In the presented case, it was observed that besides being less cytotoxic, tricalcium silicates cement stimulates the cell function, once an increase in mineralized deposits was observed (Figure 4b). On the opposite, the more cytotoxic calcium hydroxide cement led to reduced mineral deposition due to cell impairment and death (Figure 4b). Additional to a qualitative evaluation, a quantitative determination can be performed (Figure 4c).
Figure 2: Metabolic activity. Metabolic activity of MDPC-23 cells treated with calcium hydroxide cement [a)] and tricalcium silicate cement [b)] soluble extracts for 24, 72, and 120 hours. The results are normalized to the control cell cultures, with a value of 100%. Significant differences are represented by *, where * means p<0.05, ** means p<0.01, and *** means p<0.001. Part of this Figure has been modified from a previous publication with permission from the publisher20. Please click here to view a larger version of this figure.
Figure 3: Cell viability, death profile, and cell morphology. Cell viability, cell death profile, and cell morphology in MDPC-23 cells subjected to treatment with calcium hydroxide and tricalcium silicate biomaterials at 6.25% and 50% concentration, after 120 hours of exposure. a) and b) Results are plotted as the percentage of living cells in apoptosis, late apoptosis or necrosis, and necrosis. Significant differences with respect to control or between conditions are represented with *, where * means p <0.05, ** means p <0.01, and *** means p <0.001. c) Cells stained with May-Grünwald Giemsa after treatment with a 50% concentration of biomaterials soluble extracts. The control group represents cells in culture in DMEM with 10% FBS. Images in the left column were obtained with a magnification of 100x, and the images in the column on the right were obtained with a magnification of 500x. Figure bars represent 100 µm. Part of this Figure has been modified from a previous publication with permission from the publisher20. Please click here to view a larger version of this figure.
Figure 4: DSP expression and mineralized nodule formation. a) MDPC-23 cells labeled by immunocytochemistry for the detection of DSP expression when subjected to treatment with calcium hydroxide and tricalcium silicate at concentrations of 50% and 6.25% after 96 hours of incubation. b) Images from cultured MDPC-23 cells stained with Alizarin Red S stain when treated with calcium hydroxide and tricalcium silicate biomaterials at concentrations of 50% and 6.25% after 120 hours of incubation. All the photographs were obtained with a magnification of 100x. Both Figure bars represent 150µm. c) Formation of calcium deposits from MDPC-23 cells treated with calcium hydroxide and tricalcium silicate after 120 hours of exposure. The results are the ratio of the absorbances of the samples and the control. Significant differences are represented by *, where * means p<0.05, ** means p<0.01, and *** means p<0.001. Part of this Figure has been modified from a previous publication with permission from the publisher20. Please click here to view a larger version of this figure.
Table 1: List of odontoblastic differentiation/function markers47-79. This table provides a list of odontoblastic markers and detection methods; some of these markers are also expressed by other tissues.
Gene or Protein | Method | References |
Alkaline Phosphatase (ALP) | Colorimetric | 47 48 |
Immunocytochemistry | 20 49 | |
Northern Blot | 50 | |
RT-PCR | 51 52 | |
Decorin (DCN) | Colorimetric ELISA | 53 |
Immunocytochemistry | 54 55 | |
RT-PCR | 53 56 | |
Dentin Matrix Protein 1 (DMP-1) | Flow cytometry | 57 |
Immunocytochemistry | 58 59 | |
Northern Blot | 50 60 | |
RT-PCR | 47 49 | |
Western Blot | 50 60 | |
Dentin Matrix Protein 2 (DMP-2) | Immunocytochemistry | 60 61 |
RT-PCR | 50 62 | |
Northern Blot | 60 | |
Western Blot | 62 | |
Dentin Phosphoprotein (DPP) | Immunocytochemistry | 63 |
Northern Blot | 63 | |
Dentin Sialoprotein (DSP)* | Immunocytochemistry | 20 60 |
Northern Blot | 60 63 | |
RT-PCR | 50 | |
Western Blot | 64 65 | |
Dentin Sialophosphoprotein (DSPP) | Flow cytometry | 57 |
Immunocytochemistry | 66 54 | |
RT-PCR | 47 49 | |
Northern Blot | 67 68 | |
Western Blot | 64 62 | |
Enamelysin/Matrix Metalloproteinase-20 (MMP-20) | Northern Blot | 68 |
RT-PCR | 49 68 | |
Nestin | Immunocytochemistry | 54 69 |
RT-PCR | 70 71 | |
Western Blot | 72 | |
Osteoadherin (OSAD) | Immunocytochemistry | 73 74 |
Northern Blot | 73 | |
RT-PCR | 75 | |
Western Blot | 73 74 | |
Osteopontin (OPN) | Immunocytochemistry | 76 |
Northern Blot | 50 | |
RT-PCR | 66 51 | |
Western Blot | 77 | |
Osteocalcin (OCN) | Immunocytochemistry | 52 |
Northern Blot | 50 | |
RT-PCR | 51 52 | |
Western Blot | 77 78 | |
Osterix (OSX)/ Transcription factor Sp7 (Sp7) | Immunocytochemistry | 54 58 |
RT-PCR | 78 | |
Western Blot | 78 79 | |
Phosphate-regulating gene with homologies to endopeptidases on X-chromosome (Phex) | Northern Blot | 68 |
RT-PCR | 49 68 | |
Western Blot | 79 | |
Runt-related transcription factor 2 (Runx2) | Immunocytochemistry | 66 52 |
RT-PCR | 66 70 | |
Western Blot | 62 77 | |
*DPP and DSP are the cleavage products of DSPP. |
This protocol was designed taking into consideration the ISO 10993-5, which refers to the evaluation of in vitro cytotoxicity of biomaterials that contact with the tissues, to evaluate the biocompatibility and to contribute to studies reproducibility21. This is a growing concern in science, and many authors are already following these recommendations in the experimental design of their in vitro studies15,22,23,24,25,26,27,28.
The methodology proposed was selected to screen the most relevant aspects of cell biology. Thus, this protocol goes beyond the recommendations, once it provides a complete approach to evaluate cytotoxicity using common assays and a complementary evaluation, including several cell parameters from phenotype to function. This complementary evaluation is important to truly assess the biomaterials effect, once viability may not translate alterations at the level of gene and protein expression, cell cycle, or secretome.
The extracts are advantageous, particularly in adherent cell lines, because there is no interference with cell attachment to the substrate and optimal culture conditions, in opposition to some direct contact approaches where materials are placed on the surface of the culture plate22,28.
Moreover, extracts allow cell exposure to different concentrations29, mimicking diffusion of substances in tissues, which simulates the clearance they undergo in vivo, particularly when they are applied in contact with extremely irrigated tissues. Direct contact tests may not accurately assess different concentrations, and indirect contact tests demonstrated potential difficulties with non-diffusion, incomplete diffusion through membranes, or reaction with agar.
Tests providing a quantitative assessment are preferred, with cell viability reduction by more than 30% being considered cytotoxic11,30. In the development of new biomaterials, if such reduction occurs, it determines the need for reformulation or abandonment. If encouraging results are achieved, further studies should be performed envisioning in vivo evaluation29,31.
In vitro tests should simulate or exaggerate the clinical conditions. Thus, the determination of appropriate surface volume ratios for extract preparation is critical. Surface to volume ratios of 1.25–6 cm2/mL were suggested. In the case of materials with surface irregularities like foams 0.1–0.2 g/mL or 6 cm2/mL are a starting point15,20,2. The ratio of 250 mm2 per mL of medium was used in representative results used in this protocol and other studies15,20.
Even if not used in this way in the clinics, the samples must be sterilized by methods that do not alter their properties. UV irradiation is frequently a good choice. This is of paramount importance to prevent microbial contamination of cell cultures11,24,32.
Extraction media include cell culture medium with or without serum, physiological saline solution, dimethylsulfoxide, or purified water, selected according to the biomaterials chemical characteristics11,33. Aiming for cell culture studies, the use of the cell culture medium is preferred since it avoids further processing steps. The conditions for extraction should be adjusted to the experimental model. In the representative results shown in this protocol, the DMEM culture medium supplemented with FBS was used for 24 ± 2 hours at 37 ± 1 °C.
Some biomaterials may leave residues in the extraction media, which may negatively affect the cell cultures. While filtration and centrifugations should be avoided, a possibility is to allow the particles to sediment before using. Another issue is the pH that may suffer alteration after extraction. Since it is not recommended to perform further adjustments11, the pH of the extracts must be measured, registered, and additional controls to isolate the pH effect must be included in the experimental design if necessary.
While this protocol was described for adherent cell cultures, simple modifications can be performed to use suspension cultures. Similarly, besides using solid biomaterials, it is possible to adapt the procedure, essentially the extraction steps, to study liquids, gels, or foams34,35,36,37.
The preparation of cell cultures with appropriate density is critical, especially on cell cultures with high duplication rate31. According to the recommended seeding density range of the cells used, if long-time incubations are planned, the reduction of the initial seeding density must be performed to avoid the problems associated with excessive confluence. In addition, highly cytotoxic materials may require higher initial seeding densities.
Besides the advantages of the extract methodology, it is not the best choice for materials where the evaluation of cell adherence is relevant. In this case, the direct contact studies must be performed38,39,40,41. Although this is a comprehensive approach, it is important to keep in mind it is an in vitro assessment, which does not totally reflect the in vivo conditions42.
A biomaterial should not only cause damage to the tissue but stimulate some of the anti-inflammatory and immunomodulant processes43,44,45,46. Thus, this protocol goes further, with the evaluation of cellular mechanisms, including cell viability and cell death profile, as well as other mechanisms of protein synthesis. The evaluation performed should allow concluding on the biomaterial bioactivity in living tissues, besides cytotoxicity.
With the explosion of new materials for medical applications, not only for dentistry but also for orthopedics, surgery, ophthalmology, cardiology, etc., the initial screenings should be made systematically. This protocol might be an important tool for researchers aiming to develop and characterize novel biomaterials.
The authors have no competing financial interests or other conflicts of interest.
We thank the following for support: GAI 2013 (Faculdade de Medicina da Universidade de Coimbra); CIBB is funded by National Funds via FCT (Foundation for Science and Technology) through the Strategic Project UIDB/04539/2020 and UIDP/04539/2020 (CIBB). We thank to Jacques Nör, University of Michigan Dental School, for providing the cell line MDPC-23.
Name | Company | Catalog Number | Comments |
Absolute ethanol | Merck Millipore | 100983 | |
Accutase | Gibco | A1110501 | StemPro Accutas Cell Dissociation Reagent |
ALDH antibody | Santa Cruz Biotechnology | SC166362 | |
Annexin V FITC | BD Biosciences | 556547 | |
Antibiotic antimycotic solution | Sigma | A5955 | |
BCA assay | Thermo Scientific | 23225 | Pierce BCA Protein Assay Kit |
Bovine serum albumin | Sigma | A9418 | |
CaCl2 | Sigma | 10035-04-8 | |
CD133 antibody | Miteny Biotec | 293C3-APC | Allophycocyanin (APC) |
CD24 antibody | BD Biosciences | 658331 | Allophycocyanin-H7 (APC-H7) |
CD44 antibody | Biolegend | 103020 | Pacific Blue (PB) |
Cell strainer | BD Falcon | 352340 | 40 µM |
Collagenase, type IV | Gibco | 17104-019 | |
cOmplete Mini | Roche | 118 361 700 0 | |
DAB + Chromogen | Dako | K3468 | |
Dithiothreitol | Sigma | 43815 | |
DMEM-F12 | Sigma | D8900 | |
DNAse I | Roche | 11284932001 | |
DSP (M-20) Antibody, 1: 100 | Santa Cruz Biotechnology | LS-C20939 | |
ECC-1 | ATCC | CRL-2923 | Human endometrium adenocarcinoma cell line |
Epidermal growth factor | Sigma | E9644 | |
Hepes 0.01 M | Sigma | MFCD00006158 | |
Fibroblast growth factor basic | Sigma | F0291 | |
Giemsa Stain, modified GS-500 | Sigma | MFCD00081642 | |
Glycerol | Dako | C0563 | |
Haemocytometer | VWR | HERE1080339 | |
HCC1806 | ATCC | CRL-2335 | Human mammary squamous cell carcinoma cell line |
Insulin, transferrin, selenium Solution | Gibco | 41400045 | |
May-Grünwald Stain MG500 | Sigma | MFCD00131580 | |
MCF7 | ATCC | HTB-22 | Human mammary adenocarcinoma cell line |
Methylcellulose | AlfaAesar | 45490 | |
NaCl | JMGS | 37040005002212 | |
Polyclonal Rabbit Anti-goat immunoglobulins / HRP, 1: 100 | Dako | G-21234 | |
Poly(2-hydroxyethyl-methacrylate | Sigma | P3932 | |
Putrescine | Sigma | P7505 | |
RL95-2 | ATCC | CRL-1671 | Human endometrium carcinoma cell line |
Sodium deoxycholic acid | JMS | EINECS 206-132-7 | |
Sodium dodecyl sulfate | Sigma | 436143 | |
Substrate Buffer | Dako | 926605 | |
Tris | JMGS | 20360000BP152112 | |
Triton-X 100 | Merck | 108603 | |
Trypan blue | Sigma | T8154 | |
Trypsin-EDTA | Sigma | T4049 | |
β-actin antibody | Sigma | A5316 |
Zapytaj o uprawnienia na użycie tekstu lub obrazów z tego artykułu JoVE
Zapytaj o uprawnieniaThis article has been published
Video Coming Soon
Copyright © 2025 MyJoVE Corporation. Wszelkie prawa zastrzeżone